UPB vs ZURA
UPB: Upstream Bio is a clinical-stage biotech developing verekitug, a potentially best-in-class monoclonal antibody targeting the TSLP receptor for the treatment of severe respiratory inflammatory diseases. ZURA: Zura Bio is developing differentiated bispecific and monoclonal antibodies targeting immune pathways in autoimmune and inflammatory diseases where current therapies leave patients with inadequate disease control.
Side-by-side fundamentals
| Metric | UPB | ZURA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $6.59 | $5.40 | |
| Market cap as of 2026-07-23 | $376M | $532M | |
| PEG as of 2026-07-23 | n/a | -0.34 | |
| Net margin as of 2026-07-23 | -4719.0% | n/a | |
| Operating margin as of 2026-07-23 | -5176.5% | n/a | |
| ROE as of 2026-07-23 | -43.8% | -54.0% | UPB higher |
| ROA as of 2026-07-23 | -42.3% | -46.3% | UPB higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | +13.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +9.5% | n/a | |
| Beta as of 2026-07-23 | 1.77 | -0.07 | |
| 1-year return as of 2026-07-22 close | -34.4% | +221.4% | ZURA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.